IN THE CLAIMS:

Please add new claims 106 to 124 as follows:

1. -78. (Cancelled)

79. (Previously Presented) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment specifically binds to an epitope of an antigen expressed by at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, wherein CM-1 antibody produced by a cell line deposited as DSM ACC 2584 specifically binds to said epitope of the antigen expressed by at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

80.-94. (Cancelled)

95. (Previously Presented) The antibody or functional fragment of claim 79, wherein said antibody or functional fragment inhibits cell proliferation of CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), or COLO-206F (DSMZ Accession No. ACC 21) cells.

96. (Previously Presented) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment induces apoptosis of at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

97. (Previously Presented) The purified antibody or functional fragment of claim 79, wherein said functional fragment is selected from the group consisting of F_V, Fab, Fab', and $F(ab')_2$.

98. (Previously Presented) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment is a human antibody.

99. (Previously Presented) The purified antibody of claim 79, wherein said antibody is a monoclonal antibody.

100. (Previously Presented) The purified antibody or functional fragment of claim 79, comprising the amino acid sequence of SEQ ID NO:1.

101. (Previously Presented) The purified antibody or functional fragment of claim 79, comprising the amino acid sequence of SEQ ID NO:3.

102. (Previously Presented) A purified antibody or antigen binding fragment comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:3.

103. (Previously Presented) A purified antibody or antigen binding fragment, wherein the antibody is produced by a cell line deposited as DSM ACC 2584.

104. (Previously Presented) The purified antibody or functional fragment of claim 79, further comprising a pharmaceutically acceptable carrier.

105. (Previously Presented) A cell that produces the purified antibody or functional fragment of claim 79.

106. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3.

107. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:3.

108. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3.

109. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:3.

110. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at

least 95% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 98% identical to the amino acid sequence of SEQ ID NO:3.

111. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 98% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:3.

112. (New) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 98% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least at least 98% identical to the amino acid sequence of SEQ ID NO:3.

113. (New) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least at least 90% identical to the amino acid sequence of SEQ ID NO:3.

114. (New) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

115. (New) The purified antibody or functional fragment of claim 79, wherein said antibody or functional fragment comprises a heavy chain variable region sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a light chain variable region sequence at least at least 90% identical to the amino acid sequence of SEQ ID NO:3.

116. (New) The purified antibody or functional fragment of claim 79, wherein said functional fragment comprises a heavy chain variable region sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:1 or SEQ ID NO:3.

117. (New) The purified antibody or functional fragment of claim 79, wherein said functional fragment comprises a heavy chain variable region sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:1 or SEQ ID NO:3.

118. (New) The purified antibody or functional fragment of claim 79, wherein said functional fragment comprises a light chain variable region sequence that is at least 98% identical to 100 contiguous amino acids of SEQ ID NO:1 or SEQ ID NO:3.

119. (New) The purified antibody or functional fragment of claim 79, wherein said functional fragment comprises a light chain variable region sequence that is at least 100% identical to 100 contiguous amino acids of SEQ ID NO:1 or SEQ ID NO:3.

120. (New) The purified antibody or functional fragment of claim 79, wherein the heavy or light chain variable region sequence has an insertion or deletion of one amino acid residue of SEQ ID NO:1 or SEQ ID NO:3.

121. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 75% identical to the amino acid sequence of SEQ ID NO:3.

122. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 80% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 80% identical to the amino acid sequence of SEQ ID NO:3.

123. (New) The purified antibody or functional fragment thereof of claim 79, wherein said antibody or functional fragment thereof comprises a heavy chain variable region sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 or a light chain variable region sequence at least 85% identical to the amino acid sequence of SEQ ID NO:3.

124. (New) A purified antibody, or a functional fragment thereof, wherein said antibody or functional fragment specifically binds to an epitope of an antigen expressed by at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, wherein CM-1 antibody comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:3 specifically binds to said epitope of the antigen expressed by at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.